Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Bliss GVS Pharma Ltd - 506197 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Setting Up "New State Of The Art Oral Solid Dosage Facility".

 Pursuant to Regulation 30(6) read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has completed the commissioning &. qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. Itis equipped with state of the art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention.
16-03-2020
Bigul

Bliss GVS Pharma Ltd - 506197 - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019

 Pursuant to Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'') read with Para B of Part A of Schedule III of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that the Members of Nomination and Remuneration Committee of the Board of Directors of the Company in its Meeting held today i.e. March 07, 2020 have approved grant of 27,61,000 Options out of 60,00,000 Options under Bliss GVS Pharma Limited- Employee Stock Options Plan 2019 to the eligible employees as per the details mentioned in Annexure A. You are requested to take the aforementioned information on your records.
07-03-2020
Bigul

Bliss GVS Pharma Ltd - 506197 - Clarification/Update Regarding A News Item Dated March 02, 2020 Under Regulation 30(11) Of The SEBI (LODR) Regulations, 2015

 Enclosed herewith Clarification/Update regarding a news item appearing in media titled 'Bliss GVS Pharma promoters under SEBI lens for insider-trading' dated March 02, 2020 (online) and March 03, 2020 in newspaper.
03-03-2020
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Resignation of Director

 Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of part A of schedule III to the said regulation, we hereby inform that due to personal reason, Mr. Mayank Mehta (DIN: 00765252) Chairman & Independent Director of the Company has tendered his resignation with effect from February 24, 2020 from Board of Directors and other Committees of the Company. Further the Company has received confirmation from Mr. Mayank Mehta that there are no other reasons for his resignation other than those which is provided in the resignation letter dated February24, 2020.. The intimation received from Mr. Mayank Mehta in this regard is attached herewith. You are requested to take above information on record.
25-02-2020
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement clippings of unaudited financial results of the Company for the quarter and nine months ended December 31, 2019 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshkati' a Regional Daily, on February 13, 2020. Kindly take the same on record.
13-02-2020
Bigul

BLISS GVS PHARMA LTD. - 506197 - Affirmation W.R.T. Appointment Of Ms. Shilpa Bhatia (DIN: 08695595) As An Independent Woman Director (''Additional Director'') Of The Company.

 With reference to captioned subject, this is hereby inform that, the Board of Directors of the Company at their meeting held on Tuesday, February 11, 2020 has approved the appointment of Ms. Shilpa Bhatia (DIN: 08695595) as an Independent Woman Director (''Additional Director'') of the Company for a term of 5 years with effect from February 11, 2020, not liable to retire by rotation (Relevant disclosures of the same have been submitted to stock exchanges on February 11, 2020). In continuation to this, this is hereby affirm that, Ms. Shilpa Bhatia (DIN: 08695595) is not debarred from holding the office of director by virtue of any SEBI order or any other authority. Kindly take the same on your record.
12-02-2020
Bigul

Bliss GVS Pharma Ltd - 506197 - Appointment Of Secretarial Auditor For The Financial Year 2019-2020

 Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board Meeting of the Company was held today i.e. on Tuesday, February 11, 2020 at the registered office of the Company. The Board has considered and approved the following: Appointment of AVS & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for the financial year 2019-2020 in place of M/s. Ramesh Chandra Mishra & Associates, Practicing Company Secretaries. Brief profile of Secretarial Auditor is enclosed.
11-02-2020
Bigul

BLISS GVS PHARMA LTD. - 506197 - Appointment Of Secretarial Auditor For The Financial Year 2019-2020

 Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board Meeting of the Company was held today i.e. on Tuesday, February 11, 2020 at the registered office of the Company. The Board has considered and approved the following: Appointment of AVS & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for the financial year 2019-2020 in place of M/s. Ramesh Chandra Mishra & Associates, Practicing Company Secretaries. Brief profile of Secretarial Auditor is enclosed.
11-02-2020
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board Meeting of the Company was held today i.e. on Tuesday, February 11, 2020 at the registered office of the Company. The Board has considered and approved the following: Pursuant to the recommendation of the Nomination & Remuneration Committee and subject to the approval of shareholders of the Company at ensuing Annual General Meeting, the Board has appointed Ms. Shilpa Bhatia (DIN: 08695595) as an Independent Woman Director ('Additional Director') of the Company for a term of 5 years with effect from February 11, 2020, not liable to retire by rotation. Brief profile of Independent Director is enclosed.
11-02-2020
Bigul

Bliss GVS Pharma Ltd - 506197 - Submission Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended December 31, 2019.

 Pursuant to Regulation 30 of SEBI (LODR), 2015, we would like to inform you that Board Meeting of the Company was held today i.e. on Tuesday, February 11, 2020 at the registered office of the Company. The Board has considered and approved the following: 1.The Unaudited Standalone and Consolidated Financial Results for the quarter and Nine months ended December 31, 2019. 2.Pursuant to the recommendation of the Nomination & Remuneration Committee and subject to the approval of shareholders of the Company at ensuing Annual General Meeting, the Board has appointed Ms. Shilpa Bhatia (DIN: 08695595) as an Independent Woman Director ('Additional Director') of the Company for a term of 5 years with effect from February 11, 2020, not liable to retire by rotation. 3. Appointment of AVS & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for the financial year 2019-2020 in place of M/s. Ramesh Chandra Mishra & Associates, Practicing Company Secretaries.
11-02-2020
Next Page
Close

Let's Open Free Demat Account